LDB3

Across TCGA pan-cancer cohorts, LDB3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LDB3 data layer compared with 21 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LDB3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LDB3 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LUSC, BLCA, and UCEC are the cancer types where LDB3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.211	0.608	<.001	24	view →
BLCA	DFS	Median	All	1.000	0.500	.030	10	view →
UCEC	DFS	Median	All	0.972	0.826	.008	10	view →
PRAD	DFS	Median	All	0.617	0.886	.010	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
ESCA	OS	Median	All	0.452	0.703	.019	3	view →
COAD	DFS	Median	All	0.508	0.786	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LDB3–LUSC (DFS)

Open the LUSC breakdown →